Duell publishes its Q1/2025 (9/24-11/24) business review on 16th of January.
Redeye retains its Q4 and 2025 forecasts for Transtema.
Q4 report due 18 February We forecast net sales of SEK 189m, EBITA of SEK 27m Trading near low end o...
Redeye comments on Sivers Semiconductors’ announcement of a new USD5.
Redeye expects a stable Q4 report from Addnode, sharing a lot of similarities with Q3.
Redeye comments on the organisational changes and their implications on forecasts and makes a previe...
Eolus signs agreement to sell 100 MW battery storage project Estimated EV for the project in the USD...
Sells Ofir to Jobindex for DKK 20m, or ~DKK 1.0/share.
Mendus’s lead asset, vididencel, is fast approaching the pivotal stages of development in acute myel...
Smart Eye has announced an agreement to license iris recognition technology from Fingerprint Cards f...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) offentliggjorde den 31 december...
Redeye comments on announcing a new pilot involving the renowned Mayo Clinic.
Redeye adjusts its estimates after Institut Bergonié terminated the collaboration agreement to explo...
Redeye provides a comment on today's news in Scandinavian ChemoTech regarding the separation of Huma...
IT market weakness hitting Proact After showing good resilience so far this year, Proact had to prof...
Tangiamo Touch Technology (”Tangiamo” eller ”bolaget”) meddelade den 19 december 2024 att bolaget ha...
Redeye comments on Maximum Entertainment’s divestment of certain assets within Merge Games which wil...
Redeye provides a brief comment on Mendus announcing that Institut Bergonié terminated the collabora...
Gapwaves entered a product sales agreement with Smartmicro worth SEK90m, with an expected ramp-up st...
Redeye comments on the recent funding by Smart Eye’s main competitor, Seeing Machines, which has ent...